Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria

Simple item page
dc.coverageDOI: 10.1038/s41598-021-96077-1
dc.creatorGarcha, Damanpreet
dc.creatorWalker, Susan P.
dc.creatorMacDonald, Teresa M.
dc.creatorHyett, Jon
dc.creatorJellins, Jessica
dc.creatorMyers, Jenny
dc.creatorIllanes, Sebastian E.
dc.creatorNien, Jhy K.
dc.creatorSchepeler, Manuel
dc.creatorKeenan, Emerson
dc.creatorWhigham, Carole Anne
dc.creatorCannon, Ping
dc.creatorMurray, Elizabeth
dc.creatorNguyen, Tuong Vi
dc.creatorKandel, Manju
dc.creatorMasci, Joshua
dc.creatorMurphy, Ciara
dc.creatorCruickshank, Tess
dc.creatorPritchard, Natasha
dc.creatorHannan, Natalie J.
dc.creatorBrownfoot, Fiona
dc.creatorRoddy Mitchell, Alexandra
dc.creatorMiddleton, Anna
dc.creatorPell, Gabrielle
dc.creatorWong, Georgia P.
dc.creatorTong, Stephen
dc.creatorKaitu’u-Lino, Tu’uhevaha J.
dc.date2021
dc.date.accessioned2025-11-18T19:54:11Z
dc.date.available2025-11-18T19:54:11Z
dc.description<p>Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy. Identifying novel biomarkers may improve detection of pregnancies at risk. This study aimed to assess syndecan-1 as a biomarker for small for gestational age (SGA) or fetal growth restricted (FGR) pregnancies and determine its molecular regulation. Circulating maternal syndecan-1 was measured in several cohorts; a large prospective cohort collected around 36 weeks’ gestation (n = 1206), a case control study from the Manchester Antenatal Vascular service (285 women sampled at 24–34 weeks’ gestation); two prospective cohorts collected on the day of delivery (36 + 3–41 + 3 weeks’ gestation, n = 562 and n = 405 respectively) and a cohort who delivered for preterm FGR (&lt; 34 weeks). Circulating syndecan-1 was consistently reduced in women destined to deliver growth restricted infants and those delivering for preterm disease. Syndecan-1 secretion was reduced by hypoxia, and its loss impaired proliferation. Matrix metalloproteinases and mitochondrial electron transport chain inhibitors significantly reduced syndecan-1 secretion, an effect that was rescued by coadministration of succinate, a mitochondrial electron transport chain activator. In conclusion, circulating syndecan-1 is reduced among cases of term and preterm growth restriction and has potential for inclusion in multi-marker algorithms to improve detection of poorly grown fetuses.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/85f27a00-ad72-4f26-8690-a79407dc9375
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/58624
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.11 (2021) date: 2021-08-16 nr.1 p.16595
dc.subjectAdult
dc.subjectArea Under Curve
dc.subjectBirth Weight
dc.subjectCell Hypoxia
dc.subjectDelivery, Obstetric
dc.subjectDiabetes, Gestational
dc.subjectElectron Transport
dc.subjectFemale
dc.subjectFetal Growth Retardation
dc.subjectGestational Age
dc.subjectHumans
dc.subjectHypertension
dc.subjectInfant, Newborn
dc.subjectInfant, Small for Gestational Age
dc.subjectMatrix Metalloproteinases
dc.subjectMetformin
dc.subjectMitochondria
dc.subjectOrgan Size
dc.subjectOverweight
dc.subjectPlacenta
dc.subjectPre-Eclampsia
dc.subjectPregnancy
dc.subjectPregnancy Complications
dc.subjectROC Curve
dc.subjectSmoking
dc.subjectSyndecan-1
dc.subjectTrophoblast
dc.titleCirculating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondriaeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE